Results 151 to 160 of about 94,112 (278)

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan, Christian Pifl, Thomas Steinkellner   +2 more
wiley   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source

Tachycardia and Positive Amphetamine Screen are Associated With True Positive-Methamphetamine Exposures in Pediatric Patients. [PDF]

J Am Coll Emerg Physicians Open
Gans D, King W, Brewer L, Nichols M, Monroe K, Rushton W.   +5 more
europepmc   +1 more source

Holistic approach to substance‐induced psychosis

Addiction, EarlyView.
Julia M. Lappin, Shane Darke, Michael Farrell   +2 more
wiley   +1 more source

Formaldehyde Emissions From 2‐Octyl Cyanoacrylate: Quantified Risk for Allergic Contact Dermatitis

Contact Dermatitis, EarlyView.
This study found that 2‐octyl cyanoacrylate skin adhesives release formaldehyde at levels up to 8.4× above EPA dermal thresholds and up to 2.41× above NIOSH airborne limits, producing exposures sufficient to provoke allergic and irritant contact dermatitis in patients.
Daniel S. Rouhani, Paul M. Villalobos, Steven Zeng, Reza Ghodsi, Kavana M. Sanjay, Simrin A. Singh, M. Mark Mofid   +6 more
wiley   +1 more source

Disruption of Dopamine Homeostasis by Psychostimulants. [PDF]

Mol Neurobiol
Torres J, Bredenkamp C, Vazquez A, Chivero ET.   +3 more
europepmc   +1 more source

Patch Testing in Individuals With Diabetes Using Medical Devices. Part 1—Contact Allergy to Baseline Series Allergens

Contact Dermatitis, EarlyView.
The contact allergy prevalence in individuals with diabetes and in diabetes medical device (MD) users is unknown. This study in 204 diabetes MD users (114 with rash to diabetes MDs, 90 without) aimed at investigating the contact allergy prevalence to baseline series allergens. Contact allergies to sesquiterpene lactone mix and myroxylon pereirae resin (
Thanisorn Sukakul, Josefin Ulriksdotter, Martin Mowitz, Magnus Bruze, Nils Hamnerius, Cecilia Svedman   +5 more
wiley   +1 more source

Methamphetamine in the Midwestern United States: a call for advocacy and action. [PDF]

Front Psychiatry
Balasanova AA, Davids M.
europepmc   +1 more source

Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCAA and the EBSB Working Groups of the ESCD, and the GEIDACC

Contact Dermatitis, EarlyView.
ABSTRACT Background Patch test results obtained with the European Baseline Series (EBS) in its current version serve both contact allergy surveillance and (re‐)assessing the diagnostic value of EBS allergens. Objectives To present results of current EBS patch testing, obtained in 59 departments in 14 European countries during 2021 and 2022.
Wolfgang Uter, S. Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Aleksandra Dugonik, Francesca Larese Filon, Ana Giménez Arnau, Cataldo Patruno, Györgyi Pónyai, Stamatis Gregoriou, Steffen Schubert, Dagmar Simon, Luca Stingeni, Skaidra Valiukevičienė, Elke Weisshaar, Thomas Werfel, Margarida Gonçalo, Marie‐L. A. Schuttelaar, ESSCAA and EBSB ESCD Working Groups, and the GEIDACC, Birger Kränke, Alexander Navarini, Philip Spring, Ulrike Beiteke, Cecilia Dietrich, Sibylle Schliemann, Detlef Becker, Swen Malte John, Nicola Wagner, Dimitra Koumaki, Maddalena Napolitano, Anna Belloni Fortina, Francesca Larese Filon, Rosella Gallo, Thomas Rustemeyer, Radoslaw Spiewak, Maja Kalac Pandurovic, Tanja Kmecl, Mojca Simončič Godnič, Nada Kecelj, Philippa Cousen, Ella Dendooven, Juan Francisco Silvestre Salvador, José Manuel Carrascosa Carrillo, Mónica Munera Campos, Esther Serra Baldrich, Gemma Melé‐Ninot, Cristina Barrabés Torrella, David Pesqué, María Antonia Pastor Nieto, Francisco Navarro Triviño, Inmaculada Ruiz Gonzales, Enrique Gómez de la Fuente, Susana Córdoba Guijarro, Francisco Javier Ortiz de Frutos, Fátima Tous Romero, Tatiana Sanz Sánchez, Pablo Chicharro Manso, Marta Andreu Barasoain, Marta Elosua González, Araceli Sánchez Gilo, Paloma Sánchez‐Pedreño Guillén, Pedro Mercader‐García, Carmen Paredes Suárez, María Elena Gatica Ortega, José Juan Pereyra Rodríguez, Javier Miquel Miquel, Mercedes Rodríguez Serna, Violeta Zaragoza Ninet, Ricardo González Pérez   +73 more
wiley   +1 more source

Attitudes to Drug Policy in Australia, 2001-2022/23: What Does This Mean for Drug Policy Reform in Australia? [PDF]

Drug Alcohol Rev
Lloyd Z, Roxburgh A.
europepmc   +1 more source